Analysts See $-0.77 EPS for Tonix Pharmaceuticals Holding Corp. (TNXP)

March 14, 2018 - By Vivian Park

 Analysts See $ 0.77 EPS for Tonix Pharmaceuticals Holding Corp. (TNXP)

Analysts expect Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) to report $-0.77 EPS on April, 16.They anticipate $1.00 EPS change or 56.50 % from last quarter’s $-1.77 EPS. After having $-0.70 EPS previously, Tonix Pharmaceuticals Holding Corp.’s analysts see 10.00 % EPS growth. It closed at $3.41 lastly. It is down 82.55% since March 14, 2017 and is downtrending. It has underperformed by 99.25% the S&P500.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Ratings Coverage

Among 3 analysts covering Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tonix Pharmaceuticals Holding Corp. had 6 analyst reports since August 20, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, June 2 by Cantor Fitzgerald. The firm has “Buy” rating by Roth Capital given on Thursday, November 9. The firm has “Outperform” rating by Oppenheimer given on Thursday, August 20. As per Wednesday, November 4, the company rating was initiated by Cantor Fitzgerald. The rating was upgraded by Roth Capital to “Buy” on Friday, August 18. As per Monday, June 26, the company rating was initiated by Aegis Capital.

Tonix Pharmaceuticals Holding Corp. engages in developing pharmaceutical and biological products to address public health challenges. The company has market cap of $26.70 million. The Company’s lead product candidate, TNX-102 SL or Tonmya, designed as a bedtime treatment for posttraumatic stress disorder , which is in Phase 3 study in the military-related PTSD population. It currently has negative earnings. The firm is also developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (investigational new drug) application stage, designed as a daytime treatment for posttraumatic stress disorder (PTSD); and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage.

More notable recent Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) news were published by: which released: “Tonix Pharmaceuticals: Good And Bad News” on March 31, 2017, also with their article: “Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China …” published on March 13, 2018, published: “Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial …” on March 12, 2018. More interesting news about Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) were released by: and their article: “Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference” published on March 06, 2018 as well as‘s news article titled: “Tonix Pharmaceuticals Holding Corp.” with publication date: June 06, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.